BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the 20 Best Investments in 2026. BioMarin Pharmaceutical Inc. (BMRN) Seen as Attractive Buy Ahead of Transcon-CNP PDUFA, Says Wells Fargo BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is next on our list. TheFly reported on February 18 that Wells Fargo & Company increased its price target for BMRN from $70 to $75 while keeping an Overweight rating. The firm believes the upcoming Transcon-CNP PDUFA may mark the final negative catalyst for BMRN, and its sum ...

Key Takeaways BioMarin reported Q4 EPS of 46 cents, beating estimates while revenues rose 17% Y/Y to $875M.Voxzogo sales jumped 31% to $273M in Q4, while BioMarin's enzyme therapies sales rose 13%.BioMarin will withdraw Roctavian after failing to find a buyer, recording a $119.2M charge in Q4.BioMarin Pharmaceutical (BMRN) reported fourth-quarter 2025 adjusted earnings per share of 46 cents, beating the Zacks Consensus Estimate of 25 cents. However, earnings declined 50% year over year, largely due to a $11 ...

BioMarin Pharmaceutical (NasdaqGS:BMRN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAlexander Hardy - CEOBrian Mueller - CFOCristin Hubbard - Chief Commercial OfficerGena Wang - Managing Director of Biotech Equity ResearchGreg Friberg - Chief Research and Development OfficerJason Gerberry - Managing DirectorMohit Bansal - Managing Director and Co-Head of Therapeutics ResearchPaul Matteis - Managing DirectorTraci McCarty - Head of Investor RelationsConference Call ParticipantsChri ...

BioMarin Pharmaceutical (NasdaqGS:BMRN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Speaker10Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioMarin Pharmaceutical fourth quarter and full year 2025 conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this ti ...

Industry Overview - The fourth-quarter 2025 reporting season for the Medical sector is nearing its final stretch, with only a few pharma and biotech companies left to report [1] - As of February 11, 73.3% of companies in the Medical sector, representing 91% of the sector's market capitalization, reported quarterly earnings, with 86.4% exceeding both earnings and sales estimates [2][10] - Overall, fourth-quarter earnings in the medical sector are expected to decrease by 0.6%, while sales are projected to rise by 10.4% compared to the previous year [4] Company Performance Johnson & Johnson - Reported strong fourth-quarter results, beating estimates for both earnings and sales [3] Novartis - Beat earnings estimates but faced revenue pressure due to generic competition for key drugs like Entresto and Promacta [3] Bristol Myers Squibb - Beat both earnings and sales estimates and issued encouraging guidance [3] Gilead Sciences - Earnings exceeded both top and bottom lines, supported by higher sales of HIV and Liver Diseases drugs [3] Bausch Health - Mixed performance with two earnings beats and two misses in the last four quarters, delivering a four-quarter average negative surprise of 6.26% [5] - Scheduled to report on February 18, with an Earnings ESP of -8.84% and a Zacks Rank 3 [7] Amicus Therapeutics - Disappointing earnings track record with three misses and one beat in the last four quarters, averaging a negative surprise of 20.21% [8] - Set to be acquired by BioMarin, with its lead drug Galafold showing solid uptake [9] BioMarin Pharmaceutical - Impressive track record, beating earnings estimates in each of the last four quarters with an average surprise of 66.51% [11] - Scheduled to report with an Earnings ESP of -3.23% and a Zacks Rank 3, driven by strong demand for its dwarfism drug Voxzogo [12] Insmed - Poor earnings track record with four consecutive misses, averaging a negative surprise of 20.64% [13] - Scheduled to report on February 19, with an Earnings ESP of +7.01% and a Zacks Rank 3 [14] - Lead drug Arikayce gaining traction, with a new drug approval marking a significant milestone [15] Madrigal Pharmaceuticals - Missed earnings expectations in three of the last four quarters, with an average negative surprise of 17.17% [16] - Scheduled to report on February 19, with an Earnings ESP of -852.37% and a Zacks Rank 4 [16][17]

Core Viewpoint - BioMarin Pharmaceutical is expected to report its Q4 and full-year 2025 results soon, with potential strong performance from its rare-disease drug Voxzogo, but there are also concerns regarding competition and revenue guidance [1][2][3][10]. Financial Performance - BioMarin's CFO indicated that Voxzogo revenue is projected to reach its highest level in Q4, contributing to an optimistic outlook for the quarter [2]. - The company raised the lower end of its 2025 revenue guidance to $3.15 billion, reflecting double-digit year-over-year growth expectations [3]. Upcoming Catalysts - The FDA has set a PDUFA date of February 28, 2026, for Palynziq's approval for adolescents with phenylketonuria, with potential EU approval also expected in the first half of the year [4]. - BioMarin plans to announce results from two Phase 3 clinical studies in the first half of 2026 and intends to file for full FDA approval of Voxzogo for achondroplasia [5]. Market Data - BioMarin's current market capitalization is $11 billion, with a gross margin of 80.64% [7]. - The stock is currently trading at $56.51, with a day's range of $55.30 to $56.72 [6][7]. Investment Considerations - There are reasons to be cautious, including reliance on large contracted ex-U.S. orders for Voxzogo, which if not fulfilled, could lead to missing Q4 estimates [8]. - Long-term uncertainty exists regarding Voxzogo's market position due to potential competition, which could impact future revenue projections [9]. - The acquisition of Amicus Therapeutics is seen as a potential growth booster, but waiting to invest may be prudent given current uncertainties [10].

Core Insights - BioMarin Pharmaceutical is targeting a preliminary revenue of $3.2 billion for 2025, with Voxzogo expected to contribute $920 million, reflecting a strong performance and a projected 27% year-over-year growth in Q4 [3][6] - The company is focusing on expanding Voxzogo's market presence and enhancing its enzyme therapies portfolio, alongside the strategic acquisition of Amicus, valued at $4.8 billion, which is expected to diversify and accelerate revenue growth [7][8] Revenue and Growth Projections - BioMarin anticipates Voxzogo's growth in achondroplasia will be supported by new country launches and deeper market penetration, particularly emphasizing early treatment decisions for infants [2][6] - The acquisition of Amicus is expected to be accretive within 12 months post-close and substantially accretive starting in 2027, with confidence in outperforming previous growth expectations for enzyme therapies [8][7] Strategic Focus and Pipeline Development - The company's strategy is built on three pillars: innovation, growth, and a value commitment, prioritizing pipeline programs with transformative potential, including BMN 333 and BMN 351 [5][6] - BioMarin plans to accelerate revenue through geographic expansion of Voxzogo and potential label expansions for other therapies, including Palynziq [4][6] Clinical and Regulatory Catalysts - BioMarin is preparing to file for full approval of Voxzogo with the FDA, leveraging extensive safety data and additional efficacy endpoints [11] - Upcoming regulatory actions include an FDA PDUFA date for Palynziq's adolescent label expansion and significant data readouts for BMN 351 and BMN 333 [12][10][13] Competitive Dynamics and Intellectual Property Strategy - The company is committed to defending its intellectual property for Voxzogo, including seeking orphan drug exclusivity and engaging in ongoing litigation to protect its market position [15][16] - BioMarin views BMN 333 as a potential long-term game changer for achondroplasia, based on its promising exposure profile [16]

BioMarin Pharmaceutical FY Conference Summary Company Overview - **Company**: BioMarin Pharmaceutical (NasdaqGS: BMRN) - **Event**: FY Conference held on January 12, 2026 - **CEO**: Alexander Hardy Key Industry Insights - BioMarin is a leader in genetically defined conditions with a strong track record of innovation, having six first-in-disease treatments and many best-in-disease treatments [6][7] - The company operates in 80 countries and has significant R&D capabilities and in-house manufacturing [6][7] Core Financial Highlights - Preliminary revenue for 2025 is projected at **$3.2 billion**, with a **15% CAGR** over the last two years [9][21] - Voxzogo, a treatment for achondroplasia, is expected to generate **$920 million** in revenue for 2025, reflecting a **27% year-over-year growth** [19][21] Strategic Pillars 1. **Innovation**: Focus on transformative potential in the pipeline, with key assets like 333 and 351 showing promise [8][12] 2. **Growth**: Significant growth rates driven by enzyme therapies and the expansion of Voxzogo into new indications and countries [9][10] 3. **Value Commitment**: Cost transformation efforts have identified **$500 million** in cost reductions, enhancing profitability and cash flow [10] Amicus Acquisition - BioMarin announced the acquisition of Amicus for an equity value of **$4.8 billion**, which is expected to enhance revenue growth and diversify the revenue base [14][15] - Key products from Amicus include: - **Galafold** for Fabry disease, currently available in **40 countries**, with plans to expand to BioMarin's **80-country footprint** [16][17] - **Pombiliti** for Pompe disease, currently reimbursed in **15 countries**, with potential for significant growth [18] Pipeline and R&D Updates - Upcoming catalysts include: - Filing for full approval of Voxzogo in achondroplasia [12][34] - Two phase 3 data readouts and label expansions expected within the year [12][24] - BMN 351 for Duchenne muscular dystrophy showing promising early results [24][25] - BMN 333 for achondroplasia demonstrating over **13-fold** increase in free CNP exposure [28] Market Position and Competition - BioMarin is focused on defending its market position for Voxzogo against potential competitors by leveraging its established safety profile and efficacy data [49][50] - The company has petitioned for orphan drug exclusivity to delay the approval of competing products for **three more years** [49] Future Outlook - BioMarin aims for sustained double-digit CAGR growth into the 2030s, supported by the integration of Amicus products and ongoing pipeline developments [22][37] - The company is optimistic about its ability to reach more patients and enhance treatment options through its expanded portfolio [15][51] Additional Notes - The adherence rate for Voxzogo is approximately **90%**, indicating strong patient retention [45] - The company emphasizes the importance of early diagnosis and treatment in achondroplasia, which is expected to drive future growth [39][40]

Core Insights - The stock market has shown strong performance in 2025, with major indices reaching record highs, indicating Wall Street's potential for wealth creation [1][2] Group 1: Visa - Visa has a strong track record, with shares climbing in 13 of the last 15 years, and only two declines of 0.3% and 3.3% in 2021 and 2022 respectively [4] - The company's performance is closely tied to economic growth, benefiting from increased consumer and business spending [5] - Visa's focus on payment facilitation rather than lending allows it to avoid capital set-asides for loan losses, enabling quicker recovery during economic downturns [6] Group 2: The Trade Desk - The Trade Desk is positioned for recovery in 2026, with midterm elections expected to boost ad spending [7] - The company's Unified ID 2.0 technology is gaining traction, which could enhance its pricing power and sustain double-digit sales growth [8] - Shares are currently valued at 18 times forward earnings, presenting a bargain compared to previous expectations of 20% to 40% annual sales growth [9] Group 3: Meta Platforms - Meta Platforms remains fundamentally attractive despite high market valuations, with its apps attracting an average of 3.54 billion daily users [11][12] - The introduction of generative AI solutions is expected to enhance ad pricing power and improve click-through rates [13] Group 4: UnitedHealth Group - UnitedHealth Group faced challenges in 2025 but has historically risen in 22 of the last 26 years [16] - The company is exiting unprofitable markets and plans to increase healthcare premiums, which should enhance its pricing power [17] - The Optum subsidiary is expected to rebound, potentially making UnitedHealth a top performer in 2026 [18] Group 5: Sirius XM Holdings - Sirius XM operates as a legal monopoly in satellite radio, generating over 75% of its revenue from subscriptions, which provides predictable cash flow [20][21] - The company has a forward P/E ratio of less than 7, representing a 46% discount to its five-year average [22][23] Group 6: BioMarin Pharmaceutical - BioMarin focuses on ultrarare-disease therapies, with its drug Voxzogo expected to exceed $1 billion in sales this year [25][26] - The company is streamlining operations and is projected to achieve mid-to-high single-digit sales growth in 2026 [27] Group 7: NextEra Energy - NextEra Energy has generated positive returns for investors in 21 of the last 24 years, benefiting from stable electricity demand [29] - The company leads in renewable energy capacity, which has reduced generation costs and supported high-single-digit EPS growth [30][31] Group 8: Okta - Okta provides essential cybersecurity services, with demand expected to grow as cyber threats persist [33][34] - The company's subscription backlog increased to nearly $4.3 billion, reflecting strong growth potential [35] Group 9: York Water - York Water is positioned for significant revenue growth if its proposed rate increase is approved, potentially increasing annual revenue by 32% [37][38] - The company has a long history of dividend payments, enhancing its appeal as a stable investment [39] Group 10: O'Reilly Automotive - O'Reilly Automotive has advanced in 21 of the last 23 years, benefiting from the increasing age of vehicles on the road [41] - The company's share-repurchase program has positively impacted its EPS, making it attractive to value investors [43]

Group 1 - BioMarin Pharmaceutical Inc. is set to acquire Amicus Therapeutics in an all-cash transaction valued at approximately $4.8 billion, with a share price of $14.50 per Amicus share [2][3] - The acquisition is expected to close in Q2 2026, pending regulatory clearances and stockholder approval [2] - This strategic move is aimed at stabilizing long-term cash flows and expanding BioMarin's leadership in rare diseases by adding two marketed therapies for lysosomal storage disorders, which generated a combined revenue of $599 million over the last four quarters [3] Group 2 - H.C. Wainwright raised BioMarin's price target to $60 from $55, maintaining a Neutral rating, indicating that Voxzogo will remain the primary driver of stock value until peak sales materialize in the 2030s [1][3] - The acquisition includes US rights to DMX-200, a Phase 3 investigational small molecule targeting focal segmental glomerulosclerosis, a rare kidney disease [3] - BioMarin develops and commercializes therapies for life-threatening rare diseases and medical conditions across various regions including the US, Europe, and Asia Pacific [4]